Spine Biologics Market Report and Forecast 2025-2034
Description
The global spine biologics market was valued at USD 3.40 Billion in 2024, driven by the rising incidence of spinal disorders, increasing geriatric population, and growing demand for minimally invasive surgeries across the globe. The market is anticipated to grow at a CAGR of 5.30% during the forecast period of 2025-2034, with the values likely to reach USD 5.70 Billion by 2034.
Spine Biologics Market Overview
Spine biologics refer to natural substances used in spinal surgery to enhance bone growth and promote healing. These materials include bone grafts, growth factors, stem cells, and synthetic materials that help in spinal fusion and repair. They are commonly used in procedures such as spinal fusion surgeries to support the regeneration of bone tissue and stabilize the spine. The goal of using spine biologics is to improve surgical outcomes, reduce healing time, and minimize the need for revision surgeries. The market for spine biologics is growing due to rising spinal disorders and increased adoption of minimally invasive techniques.
Spine Biologics Market Growth Drivers
Innovative Allograft Launches Strengthening Market Growth
The market is experiencing significant growth due to continuous advancements in graft technology and increased clinical adoption. For instance, in April 2025, Spine Wave announced the full launch of Tempest® DCF Demineralized Cortical Fibers, expanding its presence in the spinal allograft segment. Composed entirely of human cortical bone with no carrier materials, this innovative biologic offers superior osteoconductive and osteoinductive properties, reinforcing clinical confidence and improving surgical outcomes, propelling market expansion through enhanced product efficacy and surgeon trust.
Spine Biologics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growing Adoption of Minimally Invasive Surgeries Driving Market Growth
Minimally invasive spinal procedures are increasingly preferred due to reduced recovery time, lower risk of complications, and shorter hospital stays. This shift is encouraging the adoption of spine biologics that support faster healing and improved fusion outcomes. The demand for less invasive techniques is pushing manufacturers to innovate biologics compatible with these advanced surgical approaches.
Expanding Geriatric Population to Elevate Spine Biologics Market Demand in the Forecast Period
The rising global geriatric population, prone to spinal degenerative conditions, significantly drives the demand for spine biologics. Older adults often require spinal fusion surgeries for conditions like spondylolisthesis or herniated discs, increasing the need for biologics that promote bone growth and healing. This demographic trend is a key factor supporting long-term market expansion.
Surge in Biologics R&D Activities to Boost Spine Biologics Market Value
Increasing number of research and development activities in biologic materials, such as growth factors and cell-based therapies, is significantly advancing the market. Companies are investing in creating next-generation solutions with enhanced osteoinductive and osteoconductive properties. These advancements are not only improving clinical outcomes but also strengthening product pipelines and accelerating regulatory approvals.
Strategic Collaborations and Product Launches to Enhance Spine Biologics Market Size
In March 2025, India’s Syngene International acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore for USD 36.5 million. This move aligns with the industry's broader efforts to reduce dependence on China by expanding production capabilities in other regions. The acquisition strengthens Syngene’s position in the global biologics market, supporting the growing demand for spine biologics and enhancing supply chain resilience, driving market growth.
Spine Biologics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Anterior Cervical Discectomy and Fusion to Lead the Segmentation by Surgery Type
The market is segmented by surgery type into anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), anterior lumbar interbody fusion (ALIF), and lateral lumbar interbody fusion (LLIF). Among these, ACDF is expected to lead the market due to its minimally invasive nature, faster recovery time, and growing clinical preference. Additionally, TLIF is gaining traction owing to its ability to provide spinal stability and reduced post-operative complications. These surgery types support increased demand for biologics, boosting segmental growth within the broader spine biologics market.
Spine Biologics Market Analysis by Region
North America is poised to hold the largest market share due to advanced healthcare infrastructure, increased spinal surgeries, and the strong presence of key players. Europe follows closely, driven by technological advancements and supportive reimbursement policies. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth owing to rising healthcare investments, a growing ageing population, and increasing awareness of minimally invasive spine procedures.
Leading Players in the Spine Biologics Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Stryker Corporation
Stryker Corporation is a global leader in medical technologies, including innovative spine biologics used in spinal fusion procedures. The company offers a comprehensive portfolio of bone grafts, synthetic materials, and ortho biologics to enhance bone healing and spinal stability. Stryker continues to invest in research and development, driving growth through advanced, minimally invasive spine solutions.
Orthofix International N.V.
Orthofix International N.V. specializes in musculoskeletal products, offering a robust range of spine biologics, including demineralized bone matrices and cellular allografts. The company focuses on regenerative solutions that promote natural bone growth, supporting spinal fusion and repair.
DePuy Synthes (Johnson & Johnson Services, Inc.)
DePuy Synthes, part of Johnson & Johnson, provides advanced spine biologic products to support fusion, regeneration, and repair in spinal procedures. With a strong commitment to clinical research, the company offers biologics that include bone graft substitutes and growth factors. DePuy Synthes leverages Johnson & Johnson’s vast resources to drive innovation and improve patient outcomes.
Zimmer Biomet
Zimmer Biomet is a prominent player in the spine biologics market, offering biologically active solutions designed to enhance spinal fusion and healing. Its product portfolio includes autograft extenders, demineralized bone matrices, and synthetic options tailored for complex spine surgeries. Zimmer Biomet combines innovation with clinical data to deliver effective and reliable spine biologic therapies.
Other key players in the market include Medtronic plc, Organogenesis Inc., Kuros Biosciences, Nutech, X-Spine Systems, Inc. (Bacterin International Holdings, Inc.).
Key Questions Answered in the Spine Biologics Market Report
Spine Biologics Market Overview
Spine biologics refer to natural substances used in spinal surgery to enhance bone growth and promote healing. These materials include bone grafts, growth factors, stem cells, and synthetic materials that help in spinal fusion and repair. They are commonly used in procedures such as spinal fusion surgeries to support the regeneration of bone tissue and stabilize the spine. The goal of using spine biologics is to improve surgical outcomes, reduce healing time, and minimize the need for revision surgeries. The market for spine biologics is growing due to rising spinal disorders and increased adoption of minimally invasive techniques.
Spine Biologics Market Growth Drivers
Innovative Allograft Launches Strengthening Market Growth
The market is experiencing significant growth due to continuous advancements in graft technology and increased clinical adoption. For instance, in April 2025, Spine Wave announced the full launch of Tempest® DCF Demineralized Cortical Fibers, expanding its presence in the spinal allograft segment. Composed entirely of human cortical bone with no carrier materials, this innovative biologic offers superior osteoconductive and osteoinductive properties, reinforcing clinical confidence and improving surgical outcomes, propelling market expansion through enhanced product efficacy and surgeon trust.
Spine Biologics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growing Adoption of Minimally Invasive Surgeries Driving Market Growth
Minimally invasive spinal procedures are increasingly preferred due to reduced recovery time, lower risk of complications, and shorter hospital stays. This shift is encouraging the adoption of spine biologics that support faster healing and improved fusion outcomes. The demand for less invasive techniques is pushing manufacturers to innovate biologics compatible with these advanced surgical approaches.
Expanding Geriatric Population to Elevate Spine Biologics Market Demand in the Forecast Period
The rising global geriatric population, prone to spinal degenerative conditions, significantly drives the demand for spine biologics. Older adults often require spinal fusion surgeries for conditions like spondylolisthesis or herniated discs, increasing the need for biologics that promote bone growth and healing. This demographic trend is a key factor supporting long-term market expansion.
Surge in Biologics R&D Activities to Boost Spine Biologics Market Value
Increasing number of research and development activities in biologic materials, such as growth factors and cell-based therapies, is significantly advancing the market. Companies are investing in creating next-generation solutions with enhanced osteoinductive and osteoconductive properties. These advancements are not only improving clinical outcomes but also strengthening product pipelines and accelerating regulatory approvals.
Strategic Collaborations and Product Launches to Enhance Spine Biologics Market Size
In March 2025, India’s Syngene International acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore for USD 36.5 million. This move aligns with the industry's broader efforts to reduce dependence on China by expanding production capabilities in other regions. The acquisition strengthens Syngene’s position in the global biologics market, supporting the growing demand for spine biologics and enhancing supply chain resilience, driving market growth.
Spine Biologics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Bone Graft
- Spine Autografts
- Spine Allografts
- Bone Graft Substitutes
- Bone Morphogenetic Proteins (BMP)
- Demineralized Bone Matrix (DMB)
- Synthetic Bone Grafts
- Platelet Rich Plasma (PRP)
- Bone Marrow Aspirate (BMAC) Therapy
- Anterior Cervical Discectomy and Fusion (ACDF)
- Transforaminal Lumbar Interbody Fusion (TLIF)
- Posterior Lumbar Interbody Fusion (PLIF)
- Anterior Lumbar Interbody Fusion (ALIF)
- Lateral Lumbar Interbody Fusion (LLIF)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Academic and Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Anterior Cervical Discectomy and Fusion to Lead the Segmentation by Surgery Type
The market is segmented by surgery type into anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), anterior lumbar interbody fusion (ALIF), and lateral lumbar interbody fusion (LLIF). Among these, ACDF is expected to lead the market due to its minimally invasive nature, faster recovery time, and growing clinical preference. Additionally, TLIF is gaining traction owing to its ability to provide spinal stability and reduced post-operative complications. These surgery types support increased demand for biologics, boosting segmental growth within the broader spine biologics market.
Spine Biologics Market Analysis by Region
North America is poised to hold the largest market share due to advanced healthcare infrastructure, increased spinal surgeries, and the strong presence of key players. Europe follows closely, driven by technological advancements and supportive reimbursement policies. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth owing to rising healthcare investments, a growing ageing population, and increasing awareness of minimally invasive spine procedures.
Leading Players in the Spine Biologics Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Stryker Corporation
Stryker Corporation is a global leader in medical technologies, including innovative spine biologics used in spinal fusion procedures. The company offers a comprehensive portfolio of bone grafts, synthetic materials, and ortho biologics to enhance bone healing and spinal stability. Stryker continues to invest in research and development, driving growth through advanced, minimally invasive spine solutions.
Orthofix International N.V.
Orthofix International N.V. specializes in musculoskeletal products, offering a robust range of spine biologics, including demineralized bone matrices and cellular allografts. The company focuses on regenerative solutions that promote natural bone growth, supporting spinal fusion and repair.
DePuy Synthes (Johnson & Johnson Services, Inc.)
DePuy Synthes, part of Johnson & Johnson, provides advanced spine biologic products to support fusion, regeneration, and repair in spinal procedures. With a strong commitment to clinical research, the company offers biologics that include bone graft substitutes and growth factors. DePuy Synthes leverages Johnson & Johnson’s vast resources to drive innovation and improve patient outcomes.
Zimmer Biomet
Zimmer Biomet is a prominent player in the spine biologics market, offering biologically active solutions designed to enhance spinal fusion and healing. Its product portfolio includes autograft extenders, demineralized bone matrices, and synthetic options tailored for complex spine surgeries. Zimmer Biomet combines innovation with clinical data to deliver effective and reliable spine biologic therapies.
Other key players in the market include Medtronic plc, Organogenesis Inc., Kuros Biosciences, Nutech, X-Spine Systems, Inc. (Bacterin International Holdings, Inc.).
Key Questions Answered in the Spine Biologics Market Report
- What was the spine biologics market value in 2024?
- What is the spine biologics market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on product type?
- What is the market segmentation based on the surgery type?
- What is the market breakup based on the end user?
- What major factors aid the spine biologics market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the spine biologics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Spine Biologics Market Overview
- 3.1 Global Spine Biologics Market Historical Value (2018-2024)
- 3.2 Global Spine Biologics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Spine Biologics Market Landscape*
- 5.1 Global Spine Biologics Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Spine Biologics Market: Product Landscape
- 5.2.1 Analysis by Product Type
- 5.2.2 Analysis by Surgery Type
- 6 Global Spine Biologics Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Spine Biologics Market Segmentation 218-2034
- 7.1 Global Spine Biologics Market (2018-2034) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Bone Graft
- 7.1.2.1 Spine Autografts
- 7.1.2.2 Spine Allografts
- 7.1.3 Bone Graft Substitutes
- 7.1.3.1 Bone Morphogenetic Proteins (BMP)
- 7.1.3.2 Demineralized Bone Matrix (DMB)
- 7.1.3.3 Synthetic Bone Grafts
- 7.1.4 Platelet Rich Plasma (PRP)
- 7.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 7.2 Global Spine Biologics Market (2018-2034) by Surgery Type
- 7.2.1 Market Overview
- 7.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 7.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 7.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 7.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 7.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 7.3 Global Spine Biologics Market (2018-2034) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospitals
- 7.3.3 Specialty Clinics
- 7.3.4 Ambulatory Surgical Centers (ASCs)
- 7.3.5 Academic and Research Institutes
- 7.3.6 Others
- 7.4 Global Spine Biologics Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Spine Biologics Market (218-2034)
- 8.1 North America Spine Biologics Market (2018-2034) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Bone Graft
- 8.1.2.1 Spine Autografts
- 8.1.2.2 Spine Allografts
- 8.1.3 Bone Graft Substitutes
- 8.1.3.1 Bone Morphogenetic Proteins (BMP)
- 8.1.3.2 Demineralized Bone Matrix (DMB)
- 8.1.3.3 Synthetic Bone Grafts
- 8.1.4 Platelet Rich Plasma (PRP)
- 8.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 8.2 North America Spine Biologics Market (2018-2034) by Surgery Type
- 8.2.1 Market Overview
- 8.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 8.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 8.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 8.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 8.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 8.3 North America Spine Biologics Market (2018-2034) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospitals
- 8.3.3 Specialty Clinics
- 8.3.4 Ambulatory Surgical Centers (ASCs)
- 8.3.5 Academic and Research Institutes
- 8.3.6 Others
- 8.4 North America Spine Biologics Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.1.1 United States of America Spine Biologics Market (2018-2034) by Product Type
- 8.4.2 Canada
- 8.4.2.1 Canada Spine Biologics Market (2018-2034) by Product Type
- 9 Europe Spine Biologics Market (218-2034)
- 9.1 Europe Spine Biologics Market (2018-2034) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Bone Graft
- 9.1.2.1 Spine Autografts
- 9.1.2.2 Spine Allografts
- 9.1.3 Bone Graft Substitutes
- 9.1.3.1 Bone Morphogenetic Proteins (BMP)
- 9.1.3.2 Demineralized Bone Matrix (DMB)
- 9.1.3.3 Synthetic Bone Grafts
- 9.1.4 Platelet Rich Plasma (PRP)
- 9.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 9.2 Europe Spine Biologics Market (2018-2034) by Surgery Type
- 9.2.1 Market Overview
- 9.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 9.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 9.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 9.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 9.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 9.3 Europe Spine Biologics Market (2018-2034) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospitals
- 9.3.3 Specialty Clinics
- 9.3.4 Ambulatory Surgical Centers (ASCs)
- 9.3.5 Academic and Research Institutes
- 9.3.6 Others
- 9.4 Europe Spine Biologics Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.1.1 United Kingdom Spine Biologics Market, By Product Type
- 9.4.2 Germany
- 9.4.2.1 Germany Spine Biologics Market (2018-2034) by Product Type
- 9.4.3 France
- 9.4.3.1 France Spine Biologics Market (2018-2034) by Product Type
- 9.4.4 Italy
- 9.4.4.1 Italy Spine Biologics Market (2018-2034) by Product Type
- 9.4.5 Others
- 10 Asia Pacific Spine Biologics Market (218-2034)
- 10.1 Asia Pacific Spine Biologics Market (2018-2034) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Bone Graft
- 10.1.2.1 Spine Autografts
- 10.1.2.2 Spine Allografts
- 10.1.3 Bone Graft Substitutes
- 10.1.3.1 Bone Morphogenetic Proteins (BMP)
- 10.1.3.2 Demineralized Bone Matrix (DMB)
- 10.1.3.3 Synthetic Bone Grafts
- 10.1.4 Platelet Rich Plasma (PRP)
- 10.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 10.2 Asia Pacific Spine Biologics Market (2018-2034) by Surgery Type
- 10.2.1 Market Overview
- 10.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 10.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 10.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 10.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 10.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 10.3 Asia Pacific Spine Biologics Market (2018-2034) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospitals
- 10.3.3 Specialty Clinics
- 10.3.4 Ambulatory Surgical Centers (ASCs)
- 10.3.5 Academic and Research Institutes
- 10.3.6 Others
- 10.4 Asia Pacific Spine Biologics Market (2018-2034) by Country
- 10.4.1 China
- 10.4.1.1 China Spine Biologics Market (2018-2034) by Product Type
- 10.4.2 Japan
- 10.4.2.1 Japan Spine Biologics Market (2018-2034) by Product Type
- 10.4.3 India
- 10.4.3.1 India Spine Biologics Market (2018-2034) by Product Type
- 10.4.4 ASEAN
- 10.4.4.1 ASEAN Spine Biologics Market (2018-2034) by Product Type
- 10.4.5 Australia
- 10.4.5.1 Australia Spine Biologics Market (2018-2034) by Product Type
- 10.4.6 Others
- 11 Latin America Spine Biologics Market (218-2034)
- 11.1 Latin America Spine Biologics Market (2018-2034) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Bone Graft
- 11.1.2.1 Spine Autografts
- 11.1.2.2 Spine Allografts
- 11.1.3 Bone Graft Substitutes
- 11.1.3.1 Bone Morphogenetic Proteins (BMP)
- 11.1.3.2 Demineralized Bone Matrix (DMB)
- 11.1.3.3 Synthetic Bone Grafts
- 11.1.4 Platelet Rich Plasma (PRP)
- 11.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 11.2 Latin America Spine Biologics Market (2018-2034) by Surgery Type
- 11.2.1 Market Overview
- 11.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 11.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 11.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 11.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 11.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 11.3 Latin America Spine Biologics Market (2018-2034) by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Specialty Clinics
- 11.3.4 Ambulatory Surgical Centers (ASCs)
- 11.3.5 Academic and Research Institutes
- 11.3.6 Others
- 11.4 Latin America Spine Biologics Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.1.1 Brazil Spine Biologics Market (2018-2034) by Product Type
- 11.4.2 Argentina
- 11.4.2.1 Argentina Spine Biologics Market (2018-2034) by Product Type
- 11.4.3 Mexico
- 11.4.3.1 Mexico Spine Biologics Market (2018-2034) by Product Type
- 11.4.4 Others
- 12 Middle East and Africa Spine Biologics Market (218-2034)
- 12.1 Middle East and Africa Spine Biologics Market (2018-2034) by Product Type
- 12.1.1 Market Overview
- 12.1.2 Bone Graft
- 12.1.2.1 Spine Autografts
- 12.1.2.2 Spine Allografts
- 12.1.3 Bone Graft Substitutes
- 12.1.3.1 Bone Morphogenetic Proteins (BMP)
- 12.1.3.2 Demineralized Bone Matrix (DMB)
- 12.1.3.3 Synthetic Bone Grafts
- 12.1.4 Platelet Rich Plasma (PRP)
- 12.1.5 Bone Marrow Aspirate (BMAC) Therapy
- 12.2 Middle East and Africa Spine Biologics Market (2018-2034) by Surgery Type
- 12.2.1 Market Overview
- 12.2.2 Anterior Cervical Discectomy and Fusion (ACDF)
- 12.2.3 Transforaminal Lumbar Interbody Fusion (TLIF)
- 12.2.4 Posterior Lumbar Interbody Fusion (PLIF)
- 12.2.5 Anterior Lumbar Interbody Fusion (ALIF)
- 12.2.6 Lateral Lumbar Interbody Fusion (LLIF)
- 12.3 Middle East and Africa Spine Biologics Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Specialty Clinics
- 12.3.4 Ambulatory Surgical Centers (ASCs)
- 12.3.5 Academic and Research Institutes
- 12.3.6 Others
- 12.4 Middle East and Africa Spine Biologics Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.1.1 Saudi Arabia Spine Biologics Market (2018-2034) by Product Type
- 12.4.2 United Arab Emirates
- 12.4.2.1 United Arab Emirates Spine Biologics Market (2018-2034) by Product Type
- 12.4.3 Nigeria
- 12.4.3.1 Nigeria Spine Biologics Market (2018-2034) by Product Type
- 12.4.4 South Africa
- 12.4.4.1 South Africa Spine Biologics Market (2018-2034) by Product Type
- 12.4.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 15 Grants Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Container Type
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by NIH Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Drug Class of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Drug Class of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Stryker Corporation
- 18.2.1 Financial Analysis
- 18.2.2 Technology Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 Orthofix International N.V.
- 18.3.1 Financial Analysis
- 18.3.2 Technology Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 DePuy Synthes (Johnson & Johnson Services, Inc.)
- 18.4.1 Financial Analysis
- 18.4.2 Technology Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 Zimmer Biomet
- 18.5.1 Financial Analysis
- 18.5.2 Technology Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 Arthrex, Inc.
- 18.6.1 Financial Analysis
- 18.6.2 Technology Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 Medtronic plc
- 18.7.1 Financial Analysis
- 18.7.2 Technology Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Organogenesis Inc.
- 18.8.1 Financial Analysis
- 18.8.2 Technology Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 Kuros Biosciences.
- 18.9.1 Financial Analysis
- 18.9.2 Technology Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 18.10 Nutech
- 18.10.1 Financial Analysis
- 18.10.2 Technology Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News and Development
- 18.10.5 Certifications
- 18.11 X-Spine Systems, Inc. (Bacterin International Holdings, Inc.)
- 18.11.1 Financial Analysis
- 18.11.2 Technology Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News and Development
- 18.11.5 Certifications
- 19 Global Spine Biologics Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
